肛门鳞状细胞癌放疗:ASTRO临床实践指南
美国放射肿瘤学会(ASTRO)针对肛管及肛缘原发性鳞状细胞癌的根治性治疗制定循证推荐,涵盖放疗适应证、同步系统治疗、局部切除/手术、放疗技术、剂量分割、靶区与危及器官约束及疗后监测。推荐多数患者采用同步5-氟尿嘧啶或卡培他滨联合丝裂霉素的根治性综合治疗,丝裂霉素可条件性替换为顺铂,并推荐调强放疗。
要点
- 推荐所有患者接受多学科评估与决策。
- 多数患者推荐同步5-氟尿嘧啶或卡培他滨联合丝裂霉素的根治性综合治疗。
- 推荐基于调强放疗的技术方法,原发肿瘤剂量4500至5940 cGy/25至33次。
核心结论
- 这些循证推荐指导局部肛门鳞状细胞癌根治性治疗的临床实践。
- 未来研究将进一步优化早期与晚期疾病的最佳放疗剂量、替代系统药物(包括免疫治疗)的应用、自适应放疗的作用及其他减少长期治疗相关毒性的策略。
研究设计与样本
- 美国放射肿瘤学会(ASTRO)召集工作组,基于系统性文献回顾,采用预定义的共识方法与证据质量及推荐强度分级系统制定本指南。
- 工作组聚焦4个关键问题:放疗适应证、同步系统治疗与局部切除/手术;合适的放疗技术;合适的放疗剂量分割方案、靶区与剂量约束;根治性治疗后的合适监测策略。
主要发现
- 推荐所有患者接受多学科评估与决策。
- 推荐多数患者采用同步5-氟尿嘧啶或卡培他滨联合丝裂霉素的根治性综合治疗,顺铂可作为丝裂霉素联合放疗的条件性替代方案。
- 部分早期疾病患者可考虑单纯局部切除。
- 放疗靶区应包括原发肿瘤/肛管与直肠,以及直肠系膜、骶前、髂内与髂外、闭孔及腹股沟淋巴结。
- 推荐基于调强放疗的治疗方法。
关键数值与推荐
- 原发肿瘤应接受4500至5940 cGy,分25至33次给予,取决于疾病分期与放疗方法。
- 临床受累淋巴结应接受5040至5400 cGy,分28至30次给予,取决于疾病分期与放疗方法。
- 选择性淋巴结区域应接受3600至4500 cGy,分20至30次给予,取决于疾病分期与放疗方法。
- 提供了正常组织剂量指导及减少急性和慢性治疗相关毒性的措施。
- 应尽量减少治疗中断。
临床怎么用
- 推荐所有患者接受多学科评估与决策。
- 推荐多数患者采用同步5-氟尿嘧啶或卡培他滨联合丝裂霉素的根治性综合治疗,顺铂可作为丝裂霉素联合放疗的条件性替代方案。
- 部分早期疾病患者可考虑单纯局部切除。
- 推荐基于调强放疗的治疗方法。
- 应尽量减少治疗中断。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This guideline provides evidence-based recommendations addressing the indications for definitive treatment of primary squamous cell carcinoma of the anal canal and anal margin. METHODS: The American Society for Radiation Oncology convened a task force to address 4 key questions focused on (1) indications for radiation therapy (RT), concurrent systemic therapy and local excision/surgery, (2) appropriate RT techniques, (3) appropriate RT dose-fractionation regimens, target volumes, and dose constraints, and (4) appropriate surveillance strategies after definitive treatment. Recommendations are based on a systematic literature review and created using a predefined consensus-based methodology and system for grading evidence quality and recommendation strength. RESULTS: Multidisciplinary evaluation and decision-making are recommended for all patients. Definitive treatment with combined modality therapy is recommended for most patients using concurrent 5-fluorouracil or capecitabine plus mitomycin, with cisplatin as a conditional alternative to mitomycin with RT. Select patients with early-stage disease may be considered for local excision alone. RT target volumes should include the primary tumor/anal canal and rectum, and mesorectal, presacral, internal and external iliac, obturator, and inguinal lymph nodes. Intensity modulated RT-based treatment approaches are recommended. The primary tumor should receive doses of 4500 to 5940 cGy in 25 to 33 fractions, and clinically involved lymph nodes should receive 5040 to 5400 cGy in 28 to 30 fractions, depending on disease stage and RT approach. Elective nodal volumes should receive 3600 to 4500 cGy in 20 to 30 fractions, depending on disease stage and RT approach. Dose guidance for normal tissues and measures to minimize acute and chronic treatment-related toxicity are provided. Treatment breaks should be minimized. Posttreatment surveillance strategies, including timing of clinical/digital exam, anoscopy, computed tomography, magnetic resonance imaging, and positron emission tomography/computed tomography, are discussed. CONCLUSIONS: These evidence-based recommendations guide clinical practice on the use of definitive therapy for localized anal squamous cell carcinoma. Future studies will further refine the optimal RT dose for early- and advanced-stage disease, use of alternative systemic agents, including immunotherapy, the role of adaptive RT, and other strategies to minimize long-term treatment-related toxicity.
引用
- Feng M, Hallemeier CL, Almada C, et al. Radiation Therapy for Anal Squamous Cell Carcinoma: An ASTRO Clinical Practice Guideline. Pract Radiat Oncol. 2025. PMID: 40023252. doi:10.1016/j.prro.2025.02.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。